You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)曾續漲11% 溢價發新股引資賽諾菲
阿思達克 08-05 11:24
信達生物(01801.HK)公佈第二季總收入超過10億人民幣。此外,該公司擬溢價發新股引資已達成戰略合作夥伴賽諾菲。該股今早一舉重越10天及20天線(34.9元),最多急漲11%高見36.4元,現報34.95元,續升6.4%,成交1,565萬股,涉資5.52億元。 信達生物公佈,擬向創新醫藥健康企業賽諾菲發行合共5,697.56萬股新股或佔擴大後股本3.73%,涉資3億歐元(折約24.17億港元),相當於每股作價42.42元(較昨天收市價溢價29.13%),所得淨額24.15億元,將用於日常業務營運。同時,信達與賽諾菲達成多項目戰略合作及許可協議,合拓兩款高潛力抗腫瘤藥物SAR408701及SAR444245在中國臨牀開發及商業化,信達無需就協議支付任何首付款。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account